Reveals how tumor presence disrupts B cell development via inflammatory cytokines in the bone marrow, implying new treatment targets.
Solid tumors induce systemic immune suppression, including impaired B lymphopoiesis in the bone marrow (BM). This study elucidates a novel mechanism by which remote tumors disrupt early B cell development. We demonstrate that tumor-bearing hosts exhibit skewed BM hematopoiesis favoring myeloid lineages at the expense of lymphoid lineages, specifically B cells. This impairment originates at the Common Lymphoid Progenitors (CLPs) stage. Mechanistically, monocytes, particularly CXCR2⁺ monocytes within the BM of tumor bearing mice leads to significantly elevated secretion of inflammatory cytokines TNF-α and IL-1β. These cytokines suppress CLPs differentiation into B cells. Furthermore, the enhanced secretion of TNF-α and IL-1β is mainly amplified by elevated levels of myeloid-derived S100A8/A9 proteins in the tumor-bearing BM microenvironment. Collectively, these findings identify the S100A8/A9 / TNF-α/IL-1β axis as a critical pathway disrupting B lymphopoiesis in cancer, revealing potential therapeutic targets to restore immune competence and improve immunotherapy responses.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: